Latest news with #AurobindoPharmaLtd.
Mint
03-07-2025
- Business
- Mint
Stock market today: Trade setup for Nifty 50 to global markets; Five stocks to buy or sell Thursday—3 July 2025
Stock Market Today: Amid weak global cues and as concerns around US trade policies continue, the benchmark Nifty-50 Index ended 0.35% lower at 25,453.40. The Bank Nifty lost 0.80% to end at 56,999.20, while realty was also under pressure, though metals, pharma, and auto sectors were among key gainers. The broader indices also ended slightly lower. As long as the Nifty is trading below 25,500, the weak sentiment is likely to continue, and the market could retest the level of 25,300 and 25,225 thereafter. If the market rises above 25,500, it could bounce back up to 25,600–25,670, as per Shrikant Chouhan, Head Equity Research, Kotak Securities. For Bank Nifty, structural support is placed in the 56,000–55,500 region, as per Bajaj Broking. Mixed global cues, particularly ahead of the impending tariff deadline, are driving investor caution. Market attention is gradually shifting to crucial Q1 earnings, which have high expectations, said Vinod Nair, Head of Research, Geojit Investments Limited Underlying trends such as robust macroeconomic fundamentals and increased government expenditure continue to support market resilience. However, being at the breach level of the recent rally, a cautiousness is expected to continue in the near term, added Nair Sumeet Bagadia, Executive Director at Choice Broking, has recommended two stock picks for today while Shiju Koothupalakkal, Senior Manager of Technical Research at Prabhudas Lilladher, has given three stock picks. These include Tata Steel Ltd., Aurobindo Pharma Ltd., HBL Engineering Ltd., Inox Green Energy Services Ltd., and Can Fin Homes Ltd. 1. Tata Steel—Bagadia recommends buying TATASTEEL at around ₹ 165.88, keeping stop-loss at ₹ 160 for a target price of ₹ 178 TATA Steel is currently trading at ₹ 165.88, demonstrating a strong uptrend following a sharp reversal from its recent lows. The stock has convincingly breached its previous resistance at ₹ 165, backed by solid price action and rising volumes. This breakout signals a shift in momentum, as the price structure now forms a series of higher highs and higher lows—an indication of a sustained bullish reversal. 2. Aurobindo Pharma Ltd.—Bagadia recommends buying AUROPHARMA at around ₹ 1158, keeping Stoploss at around ₹ 1117 for a target price of ₹ 1240 AUROPHARMA is currently trading at ₹ 1158, having recently rebounded from a key support zone. The stock has broken out of a falling trendline on the daily timeframe while forming a Morning Star candlestick pattern, which is an early signal of potential trend reversal. This bullish breakout is further validated by rising trading volumes, indicating renewed buying interest and strengthening market sentiment 3. HBL Engineering Ltd.—Koothupalakkal recommends buying HBL ENGINEERING at around ₹ 626.85 for a target price of ₹ 657, keeping Stop loss at ₹ 612 The stock has indicated an ascending trend with a series of higher bottom formation patterns on the daily chart, taking support near the confluence of the 200-period MA and 50-EMA level at the ₹ 560 zone, improving the bias and anticipation for further upward movement in the coming sessions. The RSI is well placed with strength indicated, signaling a buy with much upside potential from the current rate to carry on with the positive move further ahead. 4. Inox Green Energy Services Ltd.-Koothupalakkal recommends buying INOX GREEN at around ₹ 156.35 for a Target price of ₹ 166, keeping Stop loss at ₹ 152 The stock has recently witnessed a decent correction, and thereafter, with consolidation for a short period, it has shown signs of improvement with a positive candle formation to anticipate for further rise in the coming sessions. The RSI is currently well positioned and has indicated a positive trend reversal to signal a buy with much upside potential visible from the current rate. With the chart technically looking good, we suggest buying the stock for an upside target of 166 level keeping the stop loss of 152 level. 5. Can Fin Homes Ltd.—Koothupalakkal recommends buying CANFIN HOMES at around ₹ 809 for a target price of ₹ 850, keeping Stop loss at ₹ 792 The stock has sustained above the important 50EMA level for quite some time with a rising trend visible, recently once again indicating a higher bottom formation taking support near the confluence of the 200-period MA and 50EMA at the ₹ 755 zone and witnessing a decent pullback with a bullish candle formation has improved the bias, and we can anticipate further rise. With the chart technically looking attractive, we suggest buying the stock for an upside target of ₹ 850, keeping the stop loss at the ₹ 792 level. Disclaimer: The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
30-05-2025
- Business
- Economic Times
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to Add (from Buy earlier) with a revised target price of Rs 1,330 (earlier Rs 1,445). The current market price of Aurobindo Pharma Ltd. is Rs 1147.95. Aurobindo Pharma, incorporated in 1986, is a Large Cap company with a market cap of Rs 66664.41 crore, operating in the Pharmaceuticals sector. ADVERTISEMENT Aurobindo Pharma's key products/revenue segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2024. Financials For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 8516.93 crore, up 4.68 % from last quarter Total Income of Rs 8135.81 crore and up 10.38 % from last year same quarter Total Income of Rs 7715.77 crore. The company has reported net profit after tax of Rs 935.02 crore in the latest quarter. The company's top management includes Mr.M Ramasubramanian Kumar, Mukherjee, Mahajan, P Vanvari, Mr.P Sarath Chandra Reddy, Makkapati, Mr.P V Ramprasad Reddy, Mr.M Madan Mohan Reddy, Mr.K Nithyananda Reddy, Pant Joshi. Company has Deloitte Haskins & Sells as its auditors. As on 31-03-2025, the company has a total of 58 Crore shares outstanding. Investment Rationale ADVERTISEMENT Aurobindo Pharma?s US sales growth (up 8.8% YoY to $470 million) in Q4FY25 was driven by gRevlimid; however, sales run-rate is likely to come down in FY26 as pricing competition intensifies, manufacturing at Pen-G plant has been temporarily halted due to fire in the coal yard near conveyor belt. However, production may resume soon post approval from Andhra Pradesh Pollution Control Board which the management expects in next couple of months. Europe business continues to grow at a faster pace and going ahead new launches may boost growth. Management expects traction in Europe to improve ahead led by new product launches and will launch biosimilars in Europe and UK in Q2FY26. Aurobindo has signed a definitive agreement with Merck Sharpe and Dohme (MSD Singapore) for contract manufacturing of innovative biologics, civil work on this plant is on and in FY27 it expects to commission this plant; revenue generation to start in FY28. ICICI Securities lowered its FY26/27E EBITDA by ~12%/8%, respectively, to factor in lower sales from Eugia. The stock currently trades at 17.1x FY26E and 14.3x FY27E earnings, and EV/EBITDA multiples of 9.1x FY26E and 7.6x FY27E. They have lowered rating on the stock to ADD (from Buy) with lower target price of Rs 1,330 (Rs 1,445 earlier), based on 16x FY27E EPS (18x FY26E EPS earlier). Key downside risks include regulatory hurdles, currency volatility and delay in US launches. Promoter/FII Holdings Promoters held 51.82 per cent stake in the company as of 31-Mar-2025, while FIIs owned 15.33 per cent, DIIs 26.23 per cent. (You can now subscribe to our ETMarkets WhatsApp channel) Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.
Economic Times
05-05-2025
- Business
- Economic Times
Indices: Stock market update: Nifty Pharma index advances 0.69%
ADVERTISEMENT ADVERTISEMENT ADVERTISEMENT NEW DELHI: The Nifty Pharma index closed on a positive note on of Biocon Ltd.(up 5.34 per cent), Aurobindo Pharma Ltd.(up 2.49 per cent), Glenmark Pharmaceuticals Ltd.(up 2.29 per cent), Natco Pharma Ltd.(up 1.76 per cent) and Lupin Ltd.(up 1.38 per cent) ended the day as top gainers in the the other hand, Dr. Reddy's Laboratories Ltd.(down 0.99 per cent), Laurus Labs Ltd.(down 0.45 per cent), J B Chemicals & Pharmaceuticals Ltd.(down 0.44 per cent) and Abbott India Ltd.(down 0.09 per cent) finished as the top losers of the Nifty Pharma index closed 0.69 per cent up at NSE Nifty50 index ended up 114.46 points at 24461.15, while the BSE Sensex stood up 294.85 points at the 50 stocks in the Nifty index, 38 ended in the green, while 12 closed in the of Vodafone Idea, YES Bank, Indian Oil Corp., Vishal Mega Mart and Swiggy were among the most traded shares on the of Godfrey Philips, Reliance Naval & Engg, Rajvir Ind, Synergy Green Ind and Navin Fluorine hit their fresh 52-week highs in today's trade, while Keerti Knowledge, GI Engineering, AGS Transact Tech, Globe Textiles(India)and Gensol Engg hit their fresh 52-week lows.
Time of India
05-05-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 0.39% in an upbeat market
NEW DELHI: The Nifty Pharma index traded positive around 10:04AM(IST)on Monday in an upbeat market. Biocon Ltd.(up 4.19 per cent), Aurobindo Pharma Ltd.(up 2.27 per cent), Natco Pharma Ltd.(up 1.62 per cent), Lupin Ltd.(up 1.6 per cent) and Laurus Labs Ltd.(up 1.04 per cent) were among the top gainers. Dr. Reddy's Laboratories Ltd.(down 0.6 per cent), J B Chemicals & Pharmaceuticals Ltd.(down 0.32 per cent), Mankind Pharma Ltd.(down 0.32 per cent), Sun Pharmaceutical Industries Ltd.(down 0.16 per cent) and Ipca Laboratories Ltd.(down 0.02 per cent) were the top losers on the index. The Nifty Pharma index was up 0.39 per cent at 21711.75 at the time of writing this report. Benchmark NSE Nifty50 index was up 132.46 points at 24479.15, while the BSE Sensex was up 428.75 points at 80930.74. Live Events Among the 50 stocks in the Nifty index, 40 were trading in the green, while 10 were in the red. Shares of Vodafone Idea, Indian Oil Corp., Vishal Mega Mart, YES Bank and Reliance Power were among the most traded shares on the NSE. Shares of Reliance Naval & Engg, Godfrey Philips, Force Motors, ARSS Infra and Anupam Rasayan India hit their fresh 52-week highs in today's trade, while Keerti Knowledge, CMI Ltd, AGS Transact Tech, Gensol Engg and Quintegra Sol hit fresh 52-week lows in trade.
Time of India
23-04-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 1.4%
NEW DELHI: The Nifty Pharma index closed on a positive note on Wednesday. Shares of Aurobindo Pharma Ltd.(up 4.98 per cent), Alkem Laboratories Ltd.(up 4.38 per cent), Torrent Pharmaceuticals Ltd.(up 2.65 per cent), Sun Pharmaceutical Industries Ltd.(up 2.37 per cent) and Lupin Ltd.(up 2.1 per cent) ended the day as top gainers in the pack. On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 4.26 per cent), Abbott India Ltd.(down 1.76 per cent), Mankind Pharma Ltd.(down 1.32 per cent) and Laurus Labs Ltd.(down 0.16 per cent) finished as the top losers of the day. The Nifty Pharma index closed 1.4 per cent up at 21738.95. Benchmark NSE Nifty50 index ended up 161.71 points at 24328.95, while the BSE Sensex stood up 520.9 points at 80116.49. Live Events Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. Shares of Vodafone Idea, Suzlon Energy, YES Bank, IDFC First Bank and Ola Electric Mobilit were among the most traded shares on the NSE. Shares of Country Condos, Choice Intnl, Rama Phosphates, Cura Tech and Paradeep Phosphates hit their fresh 52-week highs in today's trade, while AGS Transact Tech, Gensol Engg, Dhanvarsha Finvest, Punjab Alkalies and BDR Buildcon hit their fresh 52-week lows.
